THE American SOCIETY of CLINICAL PSYCHOPHARMACOLOGY SURVEY of PSYCHOPHARMACOLOGISTS' PRACTICE PATTERNS for the TREATMENT of MOOD DISORDERS

Depression and Anxiety

Volumn 32, Issue 8, 2015, Pages 605-613

  Goldberg, Joseph F ^a   Freeman, Marlene P ^b,c   Balon, Richard ^d   Citrome, Leslie ^e   Thase, Michael E ^f,g   Kane, John M ^h,i   Fava, Maurizio ^b,c  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e NEW YORK MEDICAL COLLEGE   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g VETERANS AFFAIRS MEDICAL CENTER   (United States)

^h Zucker Hillside Hospital North Shore Long Island Jewish Health System ^*  (United States)

ⁱ DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

Author keywords

antidepressant; antipsychotic; depression; mood stabilizer; psychopharmacology; survey

Indexed keywords

AMFEBUTAMONE; ANTICONVULSIVE AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; LAMOTRIGINE; OLANZAPINE; QUETIAPINE; SEROTONIN UPTAKE INHIBITOR; ANTIDEPRESSANT AGENT; NEUROLEPTIC AGENT;

ADULT; BIPOLAR I DISORDER; BRAIN DEPTH STIMULATION; CLINICAL FEATURE; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG USE; FEMALE; HUMAN; MAJOR DEPRESSION; MALE; MEDICAL SOCIETY; MOOD DISORDER; PHARMACEUTICAL CARE; PHARMACOGENETICS; PREGNANCY; PRIORITY JOURNAL; PROFESSIONAL PRACTICE; PSYCHOPHARMACOLOGY; CLINICAL PRACTICE; HEALTH CARE SURVEY; MIDDLE AGED; MOOD DISORDERS; PROCEDURES; UNITED STATES;

ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; FEMALE; HEALTH CARE SURVEYS; HUMANS; MALE; MIDDLE AGED; MOOD DISORDERS; PRACTICE PATTERNS, PHYSICIANS'; PSYCHOPHARMACOLOGY; SOCIETIES, MEDICAL; UNITED STATES;

EID: 84937857105     PISSN: 10914269     EISSN: 15206394     Source Type: Journal    
DOI: 10.1002/da.22378     Document Type: Conference Paper

References (44)

1. Fava M, Rush AJ,. Current status of augmentation and combination treatments for major depressive disorder: a literature review and a proposal for a novel approach to improve practice. Psychother Psychosom 2006; 75 (3): 139-153.
2. Rush AJ, Trivedi MH, Wisniewski SR, et al., Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 2006; 354 (12): 1231-1242.
3. Trivedi MH, Fava M, Wisniewski SR, et al., Medication augmentation after the failure of SSRIs for depression. N Engl J Med 2006; 354 (12): 1243-1252.
4. Thase ME, Friedman ES, Biggs MM, et al., Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR D report. Am J Psychiatry 2007; 164 (5): 739-752.
5. Rush AJ, Wisniewski SR, Warden D, et al., Selecting among second-step antidepressant medication monotherapies: predictive value of clinical, demographic, or first-step treatment failures. Arch Gen Psychiatry 2008; 65: 870-880.
6. Rush AJ, Trivedi MH, Wisniewski SR, et al., Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR D report. Am J Psychiatry 2006; 163 (11): 1905-1917.
7. Petersen T, Papakostas GI, Pasternak MA, et al., Empirical testing of two models for staging antidepressant treatment resistance. J Clin Psychopharmacol 2005; 25: 335-341.
8. Parker G, Brotchie H,. Do the old psychostimulant drugs have a role in managing treatment- resistant depression? Acta Psychiatr Scand 2010; 121 (4): 308-314.
9. McElroy SL, Martens BE, Mori N, et al., Adjunctive lisdexamfetamine in bipolar depression: a preliminary randomized, placebo controlled trial. Int Clin Psychopharmacol 2015; 30 (1): 6-13.
10. Ruhé HG, Huyser J, Swinkels JA, Schene AH,. Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review. J Clin Psychiatry 2006; 67 (12): 1836-185.
11. Mischoulon D, Nierenberg AA, Kizilbash L, et al., Strategies for managing depression refractory to selective serotonin reuptake inhibitor treatment: a survey of clinicians. Can J Psychiatry 2000; 45 (5): 476-481.
12. Nelson JC, Papakostas GI,. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry 2009; 166 (9): 980-991.
13. Fava M, Rush AJ, Alpert JE, et al., Difference in treatment outcome in patients with anxious versus nonanxious depression: a STAR D report. Am J Psychiatry 2008; 165 (3): 342-351.
14. Chan HN, Rush AJ, Nierenberg AA, et al., Correlates and outcomes of depressed out- patients with greater and fewer anxious symptoms: a CO-MED report. Int J Neuropsychopharmacol 2012; 15 (10): 1387-1399.
15. Blier P, Ward HE, Tremblay P, et al., Combination of antidepressant medications from treatment initiation for major depressive disorder. Am J Psychiatry 2010; 167 (3): 281-288.
16. Fawcett J, Barkin RL,. A meta-analysis of eight randomized, double-blind, controlled trials of mirtazapine for the treatment of patients with major depression and symptoms of anxiety. J Clin Psychiatry 1998; 59 (3): 123-127.
17. Vulink NC, Figee M, Denys D,. Review of atypical antipsychotics in anxiety. Eur Neuropsychopharmacol 2011; 21 (6): 429-449.
18. Zimmerman M, Posternak MA, Attiullah N, et al., Why isn't bupropion the most frequently prescribed antidepressant? J Clin Psychiatry 2005; 66 (5): 603-610.
19. Papakostas GI, Stahl SM, Krishen A, et al., Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of major depressive disorder with high levels of anxiety (anxious depression): a pooled analysis of 10 studies. J Clin Psychiatry 2008; 69: 1287-1292.
20. Stewart JW, McGrath PJ, Liebowitz MR, et al., Treatment outcome validation of DSM-III depressive subtypes. Clinical usefulness in outpatients with mild to moderate depression. Arch Gen Psychiatry 1985; 42 (12): 1148-1153.
21. Kleber RJ., A double-blind comparative study of desipramine hydrochloride and diazepam in the control of mixed anxiety/depression symptomatology. J Clin Psychiatry 1979; 40 (4): 165-170.
22. Ravaris CL, Nies A, Robinson DS, et al., A multiple-dose, controlled study of phenelzine in depression-anxiety states. Arch Gen Psychiatry 1976; 33 (3): 347-350.
23. Paykel ES, Rowan PR, Parker RR, Bhat AV,. Response to phenelzine and amitriptyline in subtypes of outpatient depression. Arch Gen Psychiatry 1982; 39 (9): 1041-1049.
24. Kayser A, Robinson DS, Yingling K, et al., The influence on panic attacks on response to phenelzine and amitriptyline in depressed outpatients. J Clin Psychopharmacol 1988; 8 (4): 246-253.
25. Pacchiarotti I, Bond DJ, Baldessarini RJ, et al., The International Society for Bipolar Disorders (ISBD) task force on antidepressant use in bipolar disorders. Am J Psychiatry 2013; 170 (11): 1249-1262.
26. Peet M., Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants. Br J Psychiatry 1994; 164 (4): 549-550.
27. Post RM, Altshuler LL, Leverich GS, et al., Mood switch in bipolar depression: comparison of adjunctive venlafaxine, bupropion and sertraline. Am J Psychiatry 2006; 189: 124-131.
28. Ghaemi SN, Ostacher MM, El-Mallakh RS, et al., Antidepressant discontinuation in bipolar depression: a systematic treatment enhancement program for bipolar disorder (STEP-BD) randomized clinical trial of long-term effectiveness and safety. J Clin Psychiatry 2010; 71 (4): 372-380.
29. Altshuler LL, Post RM, Hellemann G, et al., Impact of antidepressant continuation after acute positive or partial treatment response for bipolar depression: a blinded, randomized study. J Clin Psychiatry 2009; 70 (4): 450-457.
30. Lim PZ, Tunis SL, Edell WS, et al., Medication prescribing patterns for patients with bipolar I disorder in hospital settings: adherence to published practice guidelines. Bipolar Disord 2001; 3 (4): 165-173.
31. Dennehy EB, Suppes T, Rush AJ, et al., Does provider adherence to a treatment guideline change clinical outcomes for patients with bipolar disorder? Results from the Texas Medication Algorithm Project. Psychol Med 2005; 35 (12): 1695-1706.
32. Samalin L, Guillaume S, Auclair C, Llorca PM,. Adherence to guidelines by French psychiatrists in their real world of clinical practice. J Nerv Ment Dis 2011; 199 (4): 239-243.
33. Smolders M, Laurant M, Verhaak P, et al., Which physician and practice characteristics are associated with adherence to evidence-based guidelines for depressive and anxiety disorders? Med Care 2010; 48 (3): 240-248.
34. Altinbaş K, Smith D, Oral ET,. Adherence to Turkish psychiatric association guideline for bipolar depression treatment in a specialized mood disorders outpatient unit. Psychiatr Danub 2011; 23 (2): 189-193.
35. Perlis RH., Use of treatment guidelines in clinical decision making in bipolar disorder: a pilot survey of clinicians. Curr Med Res Opin 2007; 23 (3): 467-475.
36. Vasudev A, Macritchie K, Vasudev K, et al., Oxcarbazepine for acute affective episodes in bipolar disorder. Cochrane Database Syst Rev 2011; 12: CD004857.
37. Amsterdam JD, Berwish NJ,. High dose tranylcypromine therapy for refractory depression. Pharmacopsychiatry 1989; 22 (1): 21-25.
38. Ferguson JM, Tourian KA, Rosas GR,. High-dose desvenlafaxine in outpatients with major depressive disorder. CNS Spectr 2012; 17 (3): 121-130.
39. Adli M, Baethge C, Heinz A, et al., Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? A systematic review. Eur Arch Psychiatry Clin Neurosci 2005; 255 (6): 387-400.
40. Thase ME, Shelton RC, Khan A,. Treatment with venlafaxine extended release after SSRI nonresponse or intolerance: a randomized comparison of standard- and higher-dosing strategies. J Clin Psychopharmacol 2006; 26 (3): 250-258.
41. Suzuki J, Connery HS, Ellison TV, Renner JA,. Preliminary survey of office-based opioid treatment practices and attitudes among psychiatrists never receiving buprenorphine training to those who received training during residency. Am J Addict 2014; 23 (6): 618-622.
42. Oldham MA, Ciraulo DA,. Use of bright light therapy among psychiatrists in Massachusetts: an e-mail survey. Prim Care Companion CNS Disord 2014; 16 (3): pii: PCC.14m01637. doi: 10.4088/PCC.14m01637. Epub 2014 Jun 26.
43. Balon R, Morreale MK, Segraves RT,. Prescribing of phosphodiesterase-5 inhibitors among psychiatrists. J Sex Marital Ther 2014; 40: 165-169
44. Arfken CL, Balon R,. Declining participation in research studies. Psychother Psychosom 2011; 80: 325-328